Cargando…
Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
BACKGROUND: Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197823/ https://www.ncbi.nlm.nih.gov/pubmed/37208644 http://dx.doi.org/10.1186/s12902-023-01360-z |
_version_ | 1785044623914172416 |
---|---|
author | Yang, Xue Wu, Yonglin Xu, Shaojie Li, Hanning Peng, Chengcheng Cui, Xiaoqing Dhoomun, Deenraj Kush Wang, Ge Xu, Tao Dong, Menglu Li, Xingrui Du, Yaying |
author_facet | Yang, Xue Wu, Yonglin Xu, Shaojie Li, Hanning Peng, Chengcheng Cui, Xiaoqing Dhoomun, Deenraj Kush Wang, Ge Xu, Tao Dong, Menglu Li, Xingrui Du, Yaying |
author_sort | Yang, Xue |
collection | PubMed |
description | BACKGROUND: Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a therapeutic target in redifferentiation strategies for thyroid cancer. METHODS: Our study integrated the differentially expressed genes acquired from the Gene Expression Omnibus database by comparing TSHR expression levels in the Cancer Genome Atlas database. We conducted functional enrichment analysis and verified the expression of these genes by RT-PCR in 68 pairs of thyroid tumor and paratumor tissues. Artificial intelligence-enabled virtual screening was combined with the VirtualFlow platform for deep docking. RESULTS: We identified five genes (KCNJ16, SLC26A4, TG, TPO, and SYT1) as potential cancer treatment targets. TSHR and KCNJ16 were downregulated in the thyroid tumor tissues, compared with paired normal tissues. In addition, KCNJ16 was lower in the vascular/capsular invasion group. Enrichment analyses revealed that KCNJ16 may play a significant role in cell growth and differentiation. The inward rectifier potassium channel 5.1 (Kir5.1, encoded by KCNJ16) emerged as an interesting target in thyroid cancer. Artificial intelligence-facilitated molecular docking identified Z2087256678_2, Z2211139111_1, Z2211139111_2, and PV-000592319198_1 (-7.3 kcal/mol) as the most potent commercially available molecular targeting Kir5.1. CONCLUSION: This study may provide greater insights into the differentiation features associated with TSHR expression in thyroid cancer, and Kir5.1 may be a potential therapeutic target in the redifferentiation strategies for recurrent and metastatic thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01360-z. |
format | Online Article Text |
id | pubmed-10197823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101978232023-05-20 Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery Yang, Xue Wu, Yonglin Xu, Shaojie Li, Hanning Peng, Chengcheng Cui, Xiaoqing Dhoomun, Deenraj Kush Wang, Ge Xu, Tao Dong, Menglu Li, Xingrui Du, Yaying BMC Endocr Disord Research BACKGROUND: Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a therapeutic target in redifferentiation strategies for thyroid cancer. METHODS: Our study integrated the differentially expressed genes acquired from the Gene Expression Omnibus database by comparing TSHR expression levels in the Cancer Genome Atlas database. We conducted functional enrichment analysis and verified the expression of these genes by RT-PCR in 68 pairs of thyroid tumor and paratumor tissues. Artificial intelligence-enabled virtual screening was combined with the VirtualFlow platform for deep docking. RESULTS: We identified five genes (KCNJ16, SLC26A4, TG, TPO, and SYT1) as potential cancer treatment targets. TSHR and KCNJ16 were downregulated in the thyroid tumor tissues, compared with paired normal tissues. In addition, KCNJ16 was lower in the vascular/capsular invasion group. Enrichment analyses revealed that KCNJ16 may play a significant role in cell growth and differentiation. The inward rectifier potassium channel 5.1 (Kir5.1, encoded by KCNJ16) emerged as an interesting target in thyroid cancer. Artificial intelligence-facilitated molecular docking identified Z2087256678_2, Z2211139111_1, Z2211139111_2, and PV-000592319198_1 (-7.3 kcal/mol) as the most potent commercially available molecular targeting Kir5.1. CONCLUSION: This study may provide greater insights into the differentiation features associated with TSHR expression in thyroid cancer, and Kir5.1 may be a potential therapeutic target in the redifferentiation strategies for recurrent and metastatic thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01360-z. BioMed Central 2023-05-19 /pmc/articles/PMC10197823/ /pubmed/37208644 http://dx.doi.org/10.1186/s12902-023-01360-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yang, Xue Wu, Yonglin Xu, Shaojie Li, Hanning Peng, Chengcheng Cui, Xiaoqing Dhoomun, Deenraj Kush Wang, Ge Xu, Tao Dong, Menglu Li, Xingrui Du, Yaying Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
title | Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
title_full | Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
title_fullStr | Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
title_full_unstemmed | Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
title_short | Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
title_sort | targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197823/ https://www.ncbi.nlm.nih.gov/pubmed/37208644 http://dx.doi.org/10.1186/s12902-023-01360-z |
work_keys_str_mv | AT yangxue targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT wuyonglin targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT xushaojie targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT lihanning targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT pengchengcheng targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT cuixiaoqing targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT dhoomundeenrajkush targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT wangge targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT xutao targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT dongmenglu targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT lixingrui targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery AT duyaying targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery |